Astellas, Affinivax’s vaccine against streptococcus pneumoniae wins breakthrough therapy status

WORLD – Astellas Pharma, a Japanese multinational pharmaceutical company, and Affinivax, a clinical stage biopharmaceutical company, have been granted a breakthrough therapy designation by the US Food and Drug Administration (FDA) for their vaccine candidate ASP3772. ASP3772 is a novel vaccine candidate designed to provide B-cell and T-cell immune protection against Streptococcus pneumoniae. The vaccine contains 24 pneumococcal polysaccharides as well as two conserved pneumococcal proteins. Pneumococcal disease is a name for any infection caused by bacteria called Streptococcus pneumoniae or pneumococcus. Streptococcus pneumoniae are lancet-shaped, gram-positive, facultative anaerobic bacteria…

Read More